NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Ha. That's funny, they used Dr. Fine because if Dr. Stupp had leveled the criticism about removing progressed tumor patients, he would have been criticizing his own trials.

Regarding Dr. Stupp,

Dr. Stupp indicated that if time from surgery to randomization were deducted, OS would not differ from what is currently seen in this patient population. .

That is simply incorrect. For instance the ITT group for his own Temodar SOC versus Temodar Dose dense (2013) study showed no statistically significant difference was observed between arms for median OS (16.6 months (SOC) v 14.9 months (Dose dense). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816958/figure/F1/

If you tag on the difference he is talking about from randomization to surgery, he got 19.6 to 17.9 (from surgery) months. DCVax-L obtained 23.1 months from surgery.

Not only that, Dr. Stupp excluded progreessors, just like his buddy Dr. Fine criticized. Plus Dr. Stupp encouraged retaining long lived pseudoprogressors. One study at ASCO has shown pseudoprogressors obtaining 34.7 mOS. DCVax-L excluded long lived pseudoprogressors from its trial.